Clinical trials: sponsored by Shanghai Hengrui Pharmaceutical Co., Ltd.
Pancreatic Cancer
A Study to Assess the Effect of Itraconazole on the Pharmacokinetics of HRS-4642 Following Intravenous Infusion in Healthy Participants
HRS-4642-103 is a single-center, single-arm, open-label, fixed-sequence study to investigate the effect of Itraconazole on the pharmacokinetics of HRS-4642 following intravenous infusion in healthy participants.
- Trial name
- NCT07906691
- Testing
- HRS4642, Itraconazole Capsules
- Where
- China
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
Systemic Treatment-naïve Pancreatic Cancer
HRS-4642 Combined With Antitumor Agents for the Treatment of Perioperative Pancreatic Cancer
The study is being conducted To evaluate the efficacy of HRS-4642 in combination with gemcitabine plus nab-paclitaxel (AG) (± SHR-1316) versus standard therapy in participants, high-risk resectable/borderline resectable…
- Trial name
- NCT07900789
- Testing
- HRS -4642 + SHR-1316+ Gemcitabine Hydrochloride for Injection+Paclitaxel for Injection, HRS -4642 + Gemcitabine Hydrochloride for Injection+Paclitaxel for Injection, Gemcitabine Hydrochloride for Injection+Paclitaxel for Injection
- Where
- 2 sites in China
- Volunteers
- 825 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
Limited-stage Small-cell Lung Cancer
A Phase II Clinical Study of SHR-7787 Injection Combined With SHR-1316 Injection in Patients With LS-SCLC
This study is an open-label, multicenter, phase II clinical study designed to evaluate the preliminary efficacy, safety, and tolerability of SHR-7787 in combination with Adebrelimab in patients with limited-stage small cell lung…
- Trial name
- NCT07798947
- Testing
- SHR-7787 Injection, SHR-1316
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
Asthma
A Trial of SHR-1905 in Subjects With Severe Uncontrolled Asthma
This study is a phase 2 study of SHR-1905 in subjects with severe uncontrolled asthma. The purpose of the study is to evaluate efficacy and safety of SHR-1905 in subjects with severe uncontrolled asthma.
- Trial name
- NCT05593250
- Testing
- SHR-1905
- Where
- China
- Volunteers
- 260 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
Advanced Solid Tumors
A Trial of SHR-7787 Injection in Patients With Advanced Solid Tumors
The study is being conducted to evaluate safety, tolerability, pharmacokinetics and preliminary efficacy of SHR-7787 injection monotherapy for patients with advanced solid tumors.
- Trial name
- NCT06605222
- Testing
- SHR-7787 injection
- Where
- China
- Volunteers
- 201 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
Stomach Neoplasms, Gastric Cancer
A Phase II Study of Irinotecan Liposome Plus Fruquintinib and Sintilimab in Second-Line PD-L1-Positive Advanced Gastric Cancer
English Translation (for ClinicalTrials.gov Patient-Friendly Summary): This is a Phase II clinical trial for patients with advanced gastric cancer (stomach cancer).
- Trial name
- NCT07819019
- Testing
- Fruquintinib, Sintilimab, Irinotecan Hydrochloride Liposome Injection (II)
- Volunteers
- 20 people
- Sponsor
- Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center
Pain
A Study of Single and Multiple Doses of HRS-6257 in Healthy Subjects
This is a phase I, randomised, single-blind placebo-controlled, 2-part study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and food effect of single and multiple oral doses of HRS-6257 in healthy…
- Trial name
- NCT07301333
- Testing
- HRS-6257
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
Advanced Solid Tumors
A Trial of SHR-A2102 With or Without Antitumor Therapy in Advanced Solid Tumors
The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A2102 for injection with or without Antitumor Therapy in Advanced Solid Tumors.
- Trial name
- NCT06417554
- Testing
- SHR-A2102, SHR-A2102 ; Adebrelimab injection, SHR-A2102 + Disitamab Vedotin For Injection
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
Moderate to Severe Atopic Dermatitis
A STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF MULTIPLE SUBCUTANEOUS INJECTIONS OF SHR-1819 IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
The study will be conducted to evaluate the safety and tolerability of SHR-1819 injection and describe the PK/PD/ADA and explore the clinical efficacy.
- Trial name
- NCT05197023
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
Esophageal Cancer, ESCC
An Exploratory Clinical Study of Accurate Efficacy Assessment of Neoadjuvant Immunotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma Based on 68Ga-FAPI ([68Ga] Fibroblast Activation Protein Inhibitor)/¹⁸F-FDG (2-Deoxy-2-[¹⁸F]Fluoro-D-glucose) Dual Imaging
This study will evaluate whether two positron emission tomography/computed tomography (PET/CT) scans performed before treatment-68Ga-FAPI and 18F-FDG-can help predict how well patients with resectable, locally advanced thoracic…
- Trial name
- NCT07770672
- Testing
- Retlirafusp Alfa Plus Chemotherapy, Adebrelimab Plus Chemotherapy
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Tan Lijie
Potentially Resectable Hepatocellular Carcinoma
Camrelizumab Combined With Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma(HCC)
The purpose of this phase 2/3 study is to investigate the efficacy and safety of camrelizumab combined with rivoceranib and hepatic arterial infusion chemotherapy (HAIC) as conversion therapy for Potentially Resectable HCC.
- Trial name
- NCT06796803
- Testing
- camrelizumab combined with rivoceranib and HAIC, camerlizumab + rivoceranib
- Where
- 2 sites in China
- Volunteers
- 398 people
- Sponsor
- Shanghai Zhongshan Hospital
Advanced Solid Tumors
A Trial of SHR-7367 in Subjects With Advanced Solid Tumors
This is a dose-escalation and dose-expansion Phase 1 trial to evaluate the safety and tolerability of SHR-7367 in subjects with advanced solid tumors.
- Trial name
- NCT05740202
- Testing
- SHR-7367
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
Multiple Myeloma
A Phase I Study of SHR-3836 in Patients With Multiple Myeloma
This is a Phase I, open-label, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of SHR-3836 in patients with multiple myeloma (MM).
- Trial name
- NCT07490613
- Testing
- SHR-3836 administered as multiple doses.
- Where
- China
- Volunteers
- 99 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
ER-Positive, HER2-Negative Breast Cancer
A Phase 1 Study of HRS8807 Monotherapy and in Combination With SHR6390 in Subjects With ER-Positive, HER2-Negative Metastatic or Locally Advanced Breast Cancer
The study is to assess safety and tolerability of HRS8807 monotherapy and in combination with SHR6390 in subjects with metastatic or locally advanced breast cancer in order to estimate the Dose-Limiting Toxicity (DLT), Maximum…
- Trial name
- NCT04993430
- Testing
- HRS8807, HRS8807、SHR6390
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysis
Investigating the Safety and Efficacy of SHR6508 Injection in the Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients : A Multicenter, Long-term Clinical Trial
This is a multicenter, single-arm, long-term safety and tolerability trial. A total of 300 subjects with chronic kidney disease on hemodialysis are planned to be enrolled.
- Trial name
- NCT06236295
- Testing
- SHR6508
- Where
- China
- Volunteers
- 303 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
SHR-A1904 Compared With Investigator's Choice of Therapy in Claudin18.2 Positive Patitens With Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
The study evaluated the overall survival (OS) of SHR-A1904 versus investigator-selected treatment in second-line CLDN18.2-positive advanced GC/GEJC patients
- Trial name
- NCT06649292
- Testing
- SHR-A1904, Paclitaxel, Docetaxel, Irinotecan
- Where
- China
- Volunteers
- 524 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
Alzheimer's Disease
Safety and Pharmacodynamics of SHR-1707 in Alzheimer's Disease Patients
Evaluate the Safety, Tolerability and Pharmacodynamics of Intravenous Administration of SHR-1707 In Patients with Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease.
- Trial name
- NCT06199037
- Testing
- SHR-1707
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
Advanced Solid Tumors
A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
This study is an open-label, multicenter Phase IB/II clinical trial to evaluate the safety, tolerability and efficacy of SHR-9839 for injection in combination with other antitumor therapies in patients with advanced solid tumors.
- Trial name
- NCT06474455
- Testing
- SHR-9839 for Injection, SHR-A1921 for Injection, SHR-A2009 for Injection
- Where
- 2 sites in China
- Volunteers
- 156 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
Alzheimer's Disease
A Study of SHR-1707 With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
This study aims to evaluate the safety, tolerability and pharmacodynamics of intravenous administration of SHR-1707 In patients with mild cognitive impairment due to Alzheimer's Disease or mild Alzheimer's Disease.
- Trial name
- NCT05681819
- Testing
- SHR-1707
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
Moderate to Severe Atopic Dermatitis
Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic Dermatitis
This trial was designed to evaluate the efficacy and safety of SHR-1819 injection in patients with atopic dermatitis.
- Trial name
- NCT05549947
- Testing
- SHR-1819
- Where
- China
- Volunteers
- 158 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.